Melatonin as a major skin protectant: From free radical scavenging to DNA damage repair

Experimental Dermatology

Volumn 17, Issue 9, 2008, Pages 713-730

  Fischer, Tobias W ^a   Slominski, Andrzej ^b   Zmijewski, Michal A ^b   Reiter, Russel J ^c   Paus, Ralf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Antioxidant; DNA; Melatonin; NQ02; Skin; UV

Indexed keywords

AMIKACIN; ASCORBIC ACID; CATALASE; CISPLATIN; DOXORUBICIN; FREE RADICAL; MELATONIN; MELATONIN RECEPTOR; MEMBRANE RECEPTOR; MEMBRANE RECEPTOR 1; MEMBRANE RECEPTOR 2; MEMBRANE RECEPTOR 3; NUCLEAR MELATONIN RECEPTOR ALPHA; NUCLEAR MELATONIN RECEPTOR ALPHA1; NUCLEAR MELATONIN RECEPTOR ALPHA4; RETINOL; SUPEROXIDE DISMUTASE; TROLOX C;

ANTIOXIDANT ACTIVITY; BASAL CELL CARCINOMA; CARDIOTOXICITY; CIRCADIAN RHYTHM; DNA DAMAGE; DNA REPAIR; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ERYTHEMA; GENE EXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; IMMUNOMODULATION; IONIZING RADIATION; NEPHROTOXICITY; NONHUMAN; PHOTOTOXICITY; RADIATION EXPOSURE; RADIATION PROTECTION; REPRODUCTIVE TOXICITY; REVIEW; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN PROTECTION; SQUAMOUS CELL CARCINOMA; TESTIS TOXICITY; ULTRAVIOLET RADIATION; VITILIGO; WEIGHT CONTROL; WOUND HEALING;

ANIMALS; DNA REPAIR; FREE RADICAL SCAVENGERS; GENE EXPRESSION; HAIR FOLLICLE; HUMANS; MELATONIN; RADIATION, IONIZING; RECEPTORS, MELATONIN; SKIN; VITILIGO;

EID: 49049087975     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00767.x     Document Type: Review

References (272)

1. Lerner A B, Case J D, Takahashi Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc 1958: 80: 2587.
2. Hardeland R F B. Ubiquitous melatonin - presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol 1996: 2: 25-45.
3. Pandi-Perumal S R, Srinivasan V, Maestroni G J, Cardinali D P, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006: 273: 2813-2838.
4. Hardeland R, Pandi-Perumal S R. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005: 2: 22.
5. Hardeland R. Antioxidative protection by melatonin: Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocr 2005: 27: 119-130.
6. Tan D X, Manchester L C, Terron M P, Flores L J, Reiter R J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007: 42: 28-42.
7. Tan D X, Reiter R J, Manchester L C et al. Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002: 2: 181-197.
8. Arendt J. Melatonin. Clin Endocrinol (Oxf) 1988: 29: 205-229.
9. Bubenik G A, Smith P S. Circadian and circannual rhythms of melatonin in plasma of male white-tailed deer and the effect of oral administration of melatonin. J Exp Zool 1987: 241: 81-89.
10. Lerchl A, Schlatt S. Influence of photoperiod on pineal melatonin synthesis, fur color, body weight, and reproductive function in the female Djungarian hamster, Phodopus sungorus. Neuroendocrinology 1993: 57: 359-364.
11. Kiefer T, Ram P T, Yuan L, Hill S M. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002: 71: 37-45.
12. Rato A G, Pedrero J G, Martinez M A, del Rio B, Lazo P S, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999: 13: 857-868.
13. Csernus V J, Nagy A D, Faluhelyi N. Development of the rhythmic melatonin secretion in the embryonic chicken pineal gland. Gen Comp Endocrinol 2007: 152: 148-153.
14. Ibraheem M, Galbraith H, Scaife J, Ewen S. Growth of secondary hair follicles of the Cashmere goat in vitro and their response to prolactin and melatonin. J Anat 1994: 185: 135-142.
15. Dardente H. Does a melatonin-dependent circadian oscillator in the pars tuberalis drive prolactin seasonal rhythmicity? J Neuroendocrinol 2007: 19: 657-666.
16. Jilg A, Moek J, Weaver D R, Korf H W, Stehle J H, von Gall C. Rhythms in clock proteins in the mouse pars tuberalis depend on MT1 melatonin receptor signalling. Eur J Neurosci 2005: 22: 2845-2854.
17. Lincoln G A. Decoding the nightly melatonin signal through circadian clockwork. Mol Cell Endocrinol 2006: 252: 69-73.
18. Wagner G C, Johnston J D, Clarke I J, Lincoln G A, Hazlerigg D G. Redefining the limits of day length responsiveness in a seasonal mammal. Endocrinology 2008: 149: 32-39.
19. Carrillo-Vico A, Calvo J R, Abreu P et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004: 18: 537-539.
20. Guerrero J M, Reiter R J. Melatonin-immune system relationships. Curr Top Med Chem 2002: 2: 67-79.
21. Herxheimer A, Petrie K J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002: 2: CD001520.
22. Waterhouse J, Reilly T, Atkinson G, Edwards B. Jet lag: Trends and coping strategies. Lancet 2007: 369: 1117-1129.
23. Bartsch C, Bartsch H, Karasek M. Melatonin in clinical oncology. Neuroendocrinol Lett 2002: 23 (Suppl. 1): 30-38.
24. Fischer T W, Zmijewski M A, Zbytek B et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 2006: 29: 665-672.
25. Kumar C A, Das U N. Effect of melatonin on two stage skin carcinogenesis in Swiss mice. Med Sci Monit 2000: 6: 471-475.
26. Winczyk K, Pawlikowski M, Guerrero J M, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine colon 38 cancer. Tumour Biol 2002: 23: 298-302.
27. Hu D N, Roberts J E. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res 1997: 7: 27-31.
28. Helton R A, Harrison W A, Kelley K, Kane M A. Melatonin interactions with cultured murine B16 melanoma cells. Melanoma Res 1993: 3: 403-413.
29. Bartsch H, Bartsch C, Fleming B. Differential effect of melatonin on slow and fast growing passages of a human melanoma cell line. Neuroendocrinol Lett 1986: 8: 289-293.
30. Tan D X, Chen L D, Poeggeler B, Manchester L C, Reiter R J. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr J 1993: 1: 57-60.
31. Reiter R J, Tan D X, Poeggeler B, Menendez-Pelaez A, Chen L D, Saarela S. Melatonin as a free radical scavenger: Implications for aging and age-related diseases. Ann N Y Acad Sci 1994: 719: 1-12.
32. Fischer T W, Elsner P. The antioxidative potential of melatonin in the skin. Curr Probl Dermatol 2001: 29: 165-174.
33. Reiter R J, Tan D X, Sainz R M, Mayo J C, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002: 54: 1299-1321.
34. Atessahin A, Sahna E, Turk G et al. Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res 2006: 41: 21-27.
35. Oz E, Erbas D, Surucu H S, Duzgun E. Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 2006: 282: 31-37.
36. Parlakpinar H, Ozer M K, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats: Protective role of melatonin. J Pineal Res 2003: 35: 85-90.
37. Karasek M, Reiter R J. Melatonin and aging. Neuroendocrinol Lett 2002: 23 (Suppl. 1): 14-16.
38. Reiter R J, Tan D X, Manchester L C, El Sawi M R. Melatonin reduces oxidant damage and promotes mitochondrial respiration: Implications for aging. Ann N Y Acad Sci 2002: 959: 238-250.
39. Reiter R J, Tan D, Kim S J et al. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Ageing Dev 1999: 110: 157-173.
40. Reiter R J, Poeggeler B, Tan D X, Chen L D, Manchester L C, Guerrero J M. Antioxidant capacity of melatonin: A novel action not requiring a receptor. Neuroendocrinol Lett 1993: 15: 103-116.
41. Leon J, Acuna-Castroviejo D, Escames G, Tan D X, Reiter R J. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005: 38: 1-9.
42. Fischer T W, Scholz G, Knoll B, Hipler U C, Elsner P. Melatonin suppresses reactive oxygen species induced by UV irradiation in leukocytes. J Pineal Res 2004: 37: 107-112.
43. Reiter R J, Tan D X, Allegra M. Melatonin: Reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuroendocrinol Lett 2002: 23 (Suppl. 1): 3-8.
44. Fischer T W, Zbytek B, Sayre R M et al. Melatonin increases survival of HaCaT keratinocytes by suppressing UV-induced apoptosis. J Pineal Res 2006: 40: 18-26.
45. Leon J, Acuna-Castroviejo D, Sainz R M, Mayo J C, Tan D X, Reiter R J. Melatonin and mitochondrial function. Life Sci 2004: 75: 765-790.
46. Fischer T W, Zmijewski M A, Wortsman J, Slominski A. Melatonin maintains mitochondrial membrane potential and attenuates activation of initiator (casp-9) and effector caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes. J Pineal Res 2008: 44: 397-407.
47. Fischer T W, Sweatman T W, Semak I, Sayre R M, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J 2006: 20: 1564-1566.
48. Tan D X, Manchester L C, Reiter R J et al. Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance. Biochim Biophys Acta 1999: 1472: 206-214.
49. Tan D X, Manchester L C, Reiter R J, Qi W, Hanes M A, Farley N J. High physiological levels of melatonin in the bile of mammals. Life Sci 1999: 65: 2523-2529.
50. Skinner D C, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 1999: 140: 4399-4405.
51. Bubenik G A, Hacker R R, Brown G M, Bartos L. Melatonin concentrations in the luminal fluid, mucosa, and muscularis of the bovine and porcine gastrointestinal tract. J Pineal Res 1999: 26: 56-63.
52. Cahill G M, Besharse J C. Light-sensitive melatonin synthesis by Xenopus photoreceptors after destruction of the inner retina. Vis Neurosci 1992: 8: 487-490.
53. Itoh M T, Ishizuka B, Kuribayashi Y, Amemiya A, Sumi Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 1999: 5: 402-408.
54. Slominski A, Wortsman J, Tobin D J. The cutaneous serotoninergic/ melatoninergic system: Securing a place under the sun. FASEB J 2005: 19: 176-194.
55. Slominski A, Pisarchik A, Semak I et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J 2002: 16: 896-898.
56. Slominski A, Fischer T W, Zmijewski M A et al. On the role of melatonin in skin physiology and pathology. Endocr 2005: 27: 137-148.
57. Slominski A, Baker J, Rosano T G et al. Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. J Biol Chem 1996: 271: 12281-12286.
58. Bubenik G A. Gastrointestinal melatonin: Localization, function, and clinical relevance. Dig Dis Sci 2002: 47: 2336-2348.
59. Kobayashi H, Kromminga A, Dunlop T W et al. A role of melatonin in neuroectodermal-mesodermal interactions: The hair follicle synthesizes melatonin and expresses functional melatonin receptors. FASEB J 2005: 19: 1710-1712.
60. Reiter R J, Tan D X. What constitutes a physiological concentration of melatonin? J Pineal Res 2003: 34: 79-80.
61. Reiter R J, Tan D X, Maldonado M D. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 2005: 39: 215-216.
62. Slominski A, Pisarchik A, Semak I, Sweatman T, Szczesniewski A, Wortsman J. Serotoninergic system in hamster skin. J Invest Dermatol 2002: 119: 934-942.
63. Gaudet S J, Slominski A, Etminan M, Pruski D, Paus R, Namboodiri M A. Identification and characterization of two isozymic forms of arylamine N-acetyltransferase in Syrian hamster skin. J Invest Dermatol 1993: 101: 660-665.
64. Maurer M, Metz M. The status quo and quo vadis of mast cells. Exp Dermatol 2005: 14: 923-929.
65. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Rev 2000: 21: 457-487.
66. Slominski A, Tobin D J, Zmijewski M A, Wortsman J, Paus R. Melatonin in the skin: Synthesis, metabolism and functions. Trends Exp Dermatol 2007: 19: 19-24.
67. Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Wortsman J. Conversion of l-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett 2002: 511: 102-106.
68. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J. Characterization of the serotoninergic system in the C57BL/6 mouse skin. Eur J Biochem 2003: 270: 3335-3344.
69. Slominski A, Pisarchik A, Johansson O et al. Tryptophan hydroxylase expression in human skin cells. Biochim Biophys Acta 2003: 1639: 80-86.
70. Schallreuter K U, Wood J M, Pittelkow M R et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994: 263: 1444-1446.
71. Schallreuter K U, Wood J M, Ziegler I et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994: 1226: 181-192.
72. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv Exp Med Biol 1996: 398: 285-289.
73. Hirata F, Hayaishi O. Studies on indoleamine 2,3-dioxygenase. I. Superoxide anion as substrate. J Biol Chem 1975: 250: 5960-5966.
74. Fujiwara M, Shibata M, Watanabe Y et al. Indoleamine 2,3-dioxygenase. Formation of l-kynurenine from l-tryptophan in cultured rabbit fineal gland. J Biol Chem 1978: 253: 6081-6085.
75. Fritsche E, Schafer C, Calles C et al. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A 2007: 104: 8851-8856.
76. Gillbro J M, Marles L K, Hibberts N A, Schallreuter K U. Autocrine catecholamine biosynthesis and the beta-adrenoceptor signal promote pigmentation in human epidermal melanocytes. J Invest Dermatol 2004: 123: 346-353.
77. Grando S A, Pittelkow M R, Schallreuter K U. Adrenergic and cholinergic control in the biology of epidermis: Physiological and clinical significance. J Invest Dermatol 2006: 126: 1948-1965.
78. Schallreuter K U, Lemke K R, Pittelkow M R, Wood J M, Korner C, Malik R. Catecholamines in human keratinocyte differentiation. J Invest Dermatol 1995: 104: 953-957.
79. Roseboom P H, Namboodiri M A, Zimonjic D B et al. Natural melatonin 'knockdown' in C57BL/6J mice: Rare mechanism truncates serotonin N-acetyltransferase. Brain Res Mol Brain Res 1998: 63: 189-197.
80. Schmuth M, Watson R E, Deplewski D, Dubrac S, Zouboulis C C, Griffiths C E. Nuclear hormone receptors in human skin. Horm Metab Res 2007: 39: 96-105.
81. Rouzaud F, Costin G E, Yamaguchi Y et al. Regulation of constitutive and UVR-induced skin pigmentation by melanocortin 1 receptor isoforms. FASEB J 2006: 20: 1927-1929.
82. Artuc M, Bohm M, Grutzkau A et al. Human mast cells in the neurohormonal network: Expression of POMC, detection of precursor proteases, and evidence for IgE-dependent secretion of alpha-MSH. J Invest Dermatol 2006: 126: 1976-1981.
83. Russell L E, Harrison W J, Bahta A W, Zouboulis C C, Burrin J M, Philpott M P. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol 2007: 16: 844-852.
84. Zouboulis C C. The human skin as a hormone target and an endocrine gland. Hormones (Athens) 2004: 3: 9-26.
85. Zouboulis C C, Chen W C, Thornton M J, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res 2007: 39: 85-95.
86. Bodo E, Kromminga A, Funk W et al. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J 2007: 21: 3346-3354.
87. Ohnemus U, Uenalan M, Inzunza J, Gustafsson J A, Paus R. The hair follicle as an estrogen target and source. Endocr Rev 2006: 27: 677-706.
88. Paus R, Bodo E, Duske U et al. Indications that normal human hair follicles have established a hypothalamic-pituitary-thyroid (HPT) axis. J Invest Dermatol 2006: 126: 104.
89. Slominski A. Neuroendocrine system of the skin. Dermatology 2005: 259: 199-208.
90. Slominski A, Wortsman J, Kohn L et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol 2002: 119: 1449-1455.
91. Reichrath J. Vitamin D and the skin: An ancient friend, revisited. Exp Dermatol 2007: 16: 618-625.
92. Slominski A, Chassalevris N, Mazurkiewicz J, Maurer M, Paus R. Murine skin as a target for melatonin bioregulation. Exp Dermatol 1994: 3: 45-50.
93. Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res 1993: 206: 189-194.
94. Slominski A, Pisarchik A, Wortsman J. Expression of genes coding melatonin and serotonin receptors in rodent skin. Biochim Biophys Acta 2004: 1680: 67-70.
95. Slominski A, Pisarchik A, Zbytek B, Tobin D J, Kauser S, Wortsman J. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol 2003: 196: 144-153.
96. Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000: 275: 31311-31317.
97. Iskander K, Paquet M, Brayton C, Jaiswal A K. Deficiency of NRH: quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004: 64: 5925-5928.
98. Hsieh T C, Wang Z, Hamby C V, Wu J M. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005: 334: 223-230.
99. Tan D X, Manchester L C, Terron M P, Flores L J, Tamura H, Reiter R J. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT(3) melatonin membrane receptor: Hypothesis and significance. J Pineal Res 2007: 43: 317-320.
100. Schallreuter K U, Rokos H, Chavan B et al. Quinones are reduced by 6-tetrahydrobiopterin in human keratinocytes, melanocytes, and melanoma cells. Free Radic Biol Med 2008: 44: 538-546.
101. Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994: 269: 28531-28534.
102. Carlberg C, Hooft van Huijsduijnen R, Staple J K, DeLamarter J F, Becker-Andre M. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol 1994: 8: 757-770.
103. Steinhilber D, Brungs M, Werz O et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995: 270: 7037-7040.
104. Wiesenberg I, Missbach M, Kahlen J P, Schrader M, Carlberg C. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995: 23: 327-333.
105. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000: 917: 387-396.
106. Chan A S, Lai F P, Lo R K, Voyno-Yasenetskaya T A, Stanbridge E J, Wong Y H. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002: 14: 249-257.
107. Kane C D, Means A R. Activation of orphan receptor-mediated transcription by Ca(2+)/calmodulin-dependent protein kinase IV. EMBO J 2000: 19: 691-701.
108. Paterson A M, Foldes A. Melatonin and farm animals: Endogenous rhythms and exogenous applications. J Pineal Res 1994: 16: 167-177.
109. Cardinali D P. [Regulation of the biologic rhythms in mammals. Function of the pineal gland]. An R Acad Nac Med (Madr) 1990: 107: 433-442.
110. Slominski A, Wortsman J, Plonka P M, Schallreuter K U, Paus R, Tobin D J. Hair follicle pigmentation. J Invest Dermatol 2005: 124: 13-21.
111. Slominski A, Tobin D J, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004: 84: 1155-1228.
112. Houssay A B, Pazo J H, Epper C E. Effects of the pineal gland upon the hair cycles in mice. J Invest Dermatol 1966: 47: 230-234.
113. Lynch G R, Epstein A L. Melatonin induced changes in gonads; pelage and thermogenic characters in the white-footed mouse, Peromyscus leucopus. Comp Biochem Physiol C 1976: 53: 67-68.
114. Hoffmann K. Photoperiodic effects in the Djungarian hamster: One minute of light during darktime mimics influence of long photoperiods on testicular recrudescence, body weight and pelage colour. Experientia 1979: 35: 1529-1530.
115. Allain D, Rougeot J. Induction of autumn moult in mink (Mustela vison Peale and Beauvois) with melatonin. Reprod Nutr Dev 1980: 20: 197-201.
116. Kuderling I, Cedrini M C, Fraschini F, Spagnesi M. Season-dependent effects of melatonin on testes and fur color in mountain hares (Lepus timidus L.). Experientia 1984: 40: 501-502.
117. Duncan M J, Goldman B D, Di Pinto M N, Stetson M H. Testicular function and pelage color have different critical daylengths in the Djungarian hamster, Phodopus sungorus sungorus. Endocrinology 1985: 116: 424-430.
118. Fischer T W, Slominski A, Tobin D J, Paus R. Melatonin and the hair follicle. J Pineal Res 2008: 44: 1-15.
119. Hipler U C, Fischer T W, Elsner P. HaCaT cell proliferation influenced by melatonin. Skin Pharmacol Appl Skin Physiol 2003: 16: 379-385.
120. Esrefoglu M, Seyhan M, Gul M, Parlakpinar H, Batcioglu K, Uyumlu B. Potent therapeutic effect of melatonin on aging skin in pinealectomized rats. J Pineal Res 2005: 39: 231-237.
121. Esrefoglu M, Gul M, Seyhan M, Parlakpinar H. Ultrastructural clues for the potent therapeutic effect of melatonin on aging skin in pinealectomized rats. Fundam Clin Pharmacol 2006: 20: 605-611.
122. Sener G, Sert G, Ozer Sehirli A, Arbak S, Gedik N, Ayanoglu-Dulger G. Melatonin protects against pressure ulcer-induced oxidative injury of the skin and remote organs in rats. J Pineal Res 2006: 40: 280-287.
123. Maldonado M D, Murillo-Cabezas F, Calvo J R et al. Melatonin as pharmacologic support in burn patients: A proposed solution to thermal injury-related lymphocytopenia and oxidative damage. Crit Care Med 2007: 35: 1177-1185.
124. Tunali T, Sener G, Yarat A, Emekli N. Melatonin reduces oxidative damage to skin and normalizes blood coagulation in a rat model of thermal injury. Life Sci 2005: 76: 1259-1265.
125. Gurlek A, Aydogan H, Parlakpinar H et al. Protective effect of melatonin on random pattern skin flap necrosis in pinealectomized rat. J Pineal Res 2004: 36: 58-63.
126. Bangha E, Elsner P, Kistler G S. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). Influence of the application time point. Dermatology 1997: 195: 248-252.
127. Bangha E, Elsner P, Kistler G S. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Arch Dermatol Res 1996: 288: 522-526.
128. Dreher F, Denig N, Gabard B, Schwindt D A, Maibach H I. Effect of topical antioxidants on UV-induced erythema formation when administered after exposure. Dermatology 1999: 198: 52-55.
129. Howes R A, Halliday G M, Damian D L. Effect of topical melatonin on ultraviolet radiation-induced suppression of Mantoux reactions in humans. Photodermatol Photoimmunol Photomed 2006: 22: 267-269.
130. Zouboulis C C. Intrinsic skin aging. A critical appraisal of the role of hormones. Hautarzt 2003: 54: 825-832.
131. Fischer T, Wigger-Alberti W, Elsner P. Melatonin in dermatology. Experimental and clinical aspects. Hautarzt 1999: 50: 5-11.
132. Drobnik J, Dabrowski R. Pinealectomy-induced elevation of collagen content in the intact skin is suppressed by melatonin application. Cytobios 1999: 100: 49-55.
133. Vesnushkin G M, Plotnikova N A, Anisimov V N. [Melatonin suppresses benz(a)pyrene-induced carcinogenesis in mice]. Vopr Onkol 2007: 53: 60-65.
134. Aoki K, Stephens D P, Zhao K, Kosiba W A, Johnson J M. Modification of cutaneous vasodilator response to heat stress by daytime exogenous melatonin administration. Am J Physiol Regul Integr Comp Physiol 2006: 291: R619-R624.
135. Krauchi K, Cajochen C, Pache M, Flammer J, Wirz-Justice A. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol Int 2006: 23: 475-484.
136. Barlow-Walden L R, Reiter R J, Abe M et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995: 26: 497-502.
137. Antolin I, Rodriguez C, Sainz R M et al. Neurohormone melatonin prevents cell damage: Effect on gene expression for antioxidant enzymes. FASEB J 1996: 10: 882-890.
138. Kotler M, Rodriguez C, Sainz R M, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998: 24: 83-89.
139. Pablos M I, Agapito M T, Gutierrez R et al. Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res 1995: 19: 111-115.
140. Reiter R J, Melchiorri D, Sewerynek E et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995: 18: 1-11.
141. Mayo J C, Sainz R M, Antoli I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002: 59: 1706-1713.
142. Rodriguez C, Mayo J C, Sainz R M et al. Regulation of antioxidant enzymes: A significant role for melatonin. J Pineal Res 2004: 36: 1-9.
143. Martin V, Sainz R M, Antolin I, Mayo J C, Herrera F, Rodriguez C. Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res 2002: 33: 204-212.
144. Taskiran D, Tanyalcin T, Sozmen E Y et al. The effects of melatonin on the antioxidant systems in experimental spinal injury. Int J Neurosci 2000: 104: 63-73.
145. Oner-Iyidogan Y, Gurdol F, Oner P. The effects of acute melatonin and ethanol treatment on antioxidant enzyme activities in rat testes. Pharmacol Res 2001: 44: 89-93.
146. Reiter R J. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995: 9: 526-533.
147. Urata Y, Honma S, Goto S et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999: 27: 838-847.
148. Masana M I, Dubocovich M L. Melatonin receptor signaling: Finding the path through the dark. Sci STKE 2001: 2001: E39.
149. Dillon D C, Easley S E, Asch B B et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 2002: 118: 451-458.
150. Brydon L, Roka F, Petit L et al. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 1999: 13: 2025-2038.
151. Kadekaro A L, Andrade L N S, Floeter-Winter L M et al. MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 2004: 36: 204-211.
152. Moretti R M, Montagnani Marelli M, Sala A, Motta M, Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. Int J Cancer 2004: 112: 87-93.
153. Naji L, Carrillo-Vico A, Guerrero J M, Calvo J R. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004: 74: 2227-2236.
154. Nosjean O, Nicolas J P, Klupsch F, Delagrange P, Canet E, Boutin J A. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001: 61: 1369-1379.
155. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 1998: 12: 143-150.
156. Yuan L, Collins A R, Dai J, Dubocovich M L, Hill S M. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002: 192: 147-156.
157. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005: 39: 99-104.
158. Pablos M, Guerrero J M, Ortiz G G, Agapito M T, Reiter R J. Both melatonin and putative nuclear melatonin receptor antagonist CGP 52608 stimulate glutathione peroxidase and glutathione reductase activities in mouse brain in vivo. Neuro Endocrinol Lett 1997: 18: 49-58.
159. Nixon A J, Choy V J, Parry A L, Pearson A J. Fiber growth initiation in hair follicles of goats treated with melatonin. J Exp Zool 1993: 267: 47-56.
160. Fischer T W, Scholz G, Knoll B, Hipler U C, Elsner P. Melatonin suppresses reactive oxygen species in UV-irradiated leukocytes more than vitamin C and trolox. Skin Pharmacol Appl Skin Physiol 2002: 15: 367-373.
161. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. Melatonin: A peroxyl radical scavenger more effective than vitamin E. Life Sci 1994: 55: L271-L276.
162. Fischer T W, Scholz G, Knoll B, Hipler U C, Elsner P. Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-stimulated leukocytes. J Pineal Res 2001: 31: 39-45.
163. Ryoo Y W, Suh S I, Mun K C, Kim B C, Lee K S. The effects of the melatonin on ultraviolet-B irradiated cultured dermal fibroblasts. J Dermatol Sci 2001: 27: 162-169.
164. Lee K S, Lee W S, Suh S I et al. Melatonin reduces ultraviolet-B induced cell damages and polyamine levels in human skin fibroblasts in culture. Exp Mol Med 2003: 35: 263-268.
165. Krutmann J. The interaction of UVA and UVB wavebands with particular emphasis on signalling. Prog Biophys Mol Biol 2006: 92: 105-107.
166. Krutmann J. Premature skin aging by ultraviolet radiation and other environmental hazards. The molecular basis. Hautarzt 2003: 54: 809-817.
167. Leccia M T, Yaar M, Allen N, Gleason M, Gilchrest B A. Solar simulated irradiation modulates gene expression and activity of antioxidant enzymes in cultured human dermal fibroblasts. Exp Dermatol 2001: 10: 272-279.
168. Kulms D, Schwarz T. Mechanisms of UV-induced signal transduction. J Dermatol 2002: 29: 189-196.
169. Scharffetter-Kochanek K, Brenneisen P, Wenk J et al. Photoaging of the skin from phenotype to mechanisms. Exp Gerontol 2000: 35: 307-316.
170. Cho J W, Kim C W, Lee K S. Modification of gene expression by melatonin in UVB-irradiated HaCaT keratinocyte cell lines using a cDNA microarray. Oncol Rep 2007: 17: 573-577.
171. Maharaj D S, Anoopkumar-Dukie S, Glass B D et al. The identification of the UV degradants of melatonin and their ability to scavenge free radicals. J Pineal Res 2002: 32: 257-261.
172. Tan D X, Manchester L C, Reiter R J, Qi W B, Karbownik M, Calvo J R. Significance of melatonin in antioxidative defense system: Reactions and products. Biol Signals Recept 2000: 9: 137-159.
173. 2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001: 15: 2294-2296.
174. 1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005: 165: 139-149.
175. 2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res 2005: 38: 107-115.
176. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003: 8: 205-213.
177. Dreher F, Gabard B, Schwindt D A, Maibach H I. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: A human study in vivo. Br J Dermatol 1998: 139: 332-339.
178. Fischer T W, Elsner P. Melatonin: A hormone, drug or cosmeceutical. In: Elsner P, Maibach H I eds. Cosmeceuticals and Active Cosmetics, Vol. 1. Boca Raton: Taylor & Francis, 2005: 413-419.
179. Kim B C, Shon B S, Ryoo Y W, Kim S P, Lee K S. Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. J Dermatol Sci 2001: 26: 194-200.
180. Scharffetter-Kochanek K, Wlaschek M, Brenneisen P, Schauen M, Blaudschun R, Wenk J. UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol Chem 1997: 378: 1247-1257.
181. Scharffetter-Kochanek K, Wlaschek M, Briviba K, Sies H. Singlet oxygen induces collagenase expression in human skin fibroblasts. FEBS Lett 1993: 331: 304-306.
182. Schwarz T. Mechanisms of UV-induced immunosuppression. Keio J Med 2005: 54: 165-171.
183. Kulms D, Zeise E, Poppelmann B, Schwarz T. DNA damage, death receptor activation and reactive oxygen species contribute to ultraviolet radiation-induced apoptosis in an essential and independent way. Oncogene 2002: 21: 5844-5851.
184. Krutmann J. Ultraviolet A radiation-induced biological effects in human skin: Relevance for photoaging and photodermatosis. J Dermatol Sci 2000: 23 (Suppl. 1): S22-S26.
185. Berneburg M, Plettenberg H, Krutmann J. Photoaging of human skin. Photodermatol Photoimmunol Photomed 2000: 16: 239-244.
186. Arck P C, Slominski A, Theoharides T C, Peters E M J, Paus R. Neuroimmunology of stress: Skin takes center stage. J Invest Dermatol 2006: 126: 1697-1704.
187. Reiter R J, Tan D X, Terron M P, Flores L J, Czarnocki Z. Melatonin and its metabolites: New findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007: 54: 1-9.
188. Krutmann J, Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Invest Dermatol 1995: 105: 67S-70S.
189. Berneburg M, Grether-Beck S, Kurten V et al. Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion. J Biol Chem 1999: 274: 15345-15349.
190. Tan D X, Manchester L C, Hardeland R et al. Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003: 34: 75-78.
191. Hardeland R, Reiter R J, Poeggeler B, Tan D X. The significance of the metabolism of the neurohormone melatonin: Antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993: 17: 347-357.
192. Fischer T W, Greif C, Fluhr J W, Wigger-Alberti W, Elsner P. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution. Skin Pharmacol Physiol 2004: 17: 190-194.
193. Tsukahara H, Shibata R, Ohshima Y et al. Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis. Life Sci 2003: 72: 2509-2516.
194. Schallreuter K U, Bahadoran P, Picardo M et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008: 17: 139-140.
195. Huang C L, Nordlund J J, Boissy R. Vitiligo: A manifestation of apoptosis? Am J Clin Dermatol 2002: 3: 301-308.
196. Nordlund J J, Majumder P P. Recent investigations on vitiligo vulgaris. Dermatol Clin 1997: 15: 69-78.
197. Slominski A, Zmijewski M, Paus R. Viewpoint 4: Melatonin hypothesis on the vitiligo pathogenesis. Exp Dermatol 2008: 17: 149-152.
198. Taieb A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 2000: 13 (Suppl. 8): 41-47.
199. Le Poole I C, Wankowicz-Kalinska A, van den Wijngaard R M, Nickoloff B J, Das P K. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004: 9: 68-72.
200. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999: 4: 91-96.
201. Dell'anna M L, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006: 19: 406-411.
202. Boissy R E, Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004: 17: 208-214.
203. Slominski A, Paus R, Bomirski A. Hypothesis: Possible role for the melatonin receptor in vitiligo: Discussion paper. J R Soc Med 1989: 82: 539-541.
204. Schallreuter K U, Gibbons N C, Zothner C, Abou Elloof M M, Wood J M. Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: More evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2007: 360: 70-75.
205. 2 stress. J Invest Dermatol 2004: 122: 307-313.
206. Dubocovich M L, Rivera-Bermudez M A, Gerdin M J, Masana M I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003: 8: d1093-d1108.
207. Hara M, Yoshida M, Nishijima H et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001: 30: 129-138.
208. Fukutomi J, Fukuda A, Fukuda S, Hara M, Terada A, Yoshida M. Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species. Life Sci 2006: 80: 254-257.
209. Dziegiel P, Murawska-Cialowicz E, Jethon Z et al. Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J Pineal Res 2003: 35: 183-187.
210. Hussein M R, Abu-Dief E E, Abd El-Reheem M H, Abd-Elrahman A. Ultrastructural evaluation of the radioprotective effects of melatonin against X-ray-induced skin damage in albino rats. Int J Exp Pathol 2005: 86: 45-55.
211. Vijayalaxmi, Reiter R J, Tan D X, Herman T S, Thomas C R Jr. Melatonin as a radioprotective agent: A review. Int J Radiat Oncol Biol Phys 2004: 59: 639-653.
212. Wambersie A, Smeesters P, Fruhling J. Exposure to ionizing radiation: radiobiological and pathogenic effects (2). Rev Med Brux 1996: 17: 75-84.
213. Karagas M R, Nelson H H, Zens M S et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology 2008: 18: 776-784.
214. Karbownik M, Reiter R J. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med 2000: 225: 9-22.
215. Karbownik M, Reiter R J, Qi W et al. Protective effects of melatonin against oxidation of guanine bases in DNA and decreased microsomal membrane fluidity in rat liver induced by whole body ionizing radiation. Mol Cell Biochem 2000: 211: 137-144.
216. Zhou G, Kawata T, Furusawa Y et al. Protective effects of melatonin against low- and high-LET irradiation. J Radiat Res (Tokyo) 2006: 47: 175-181.
217. Von Sonntag C. The Chemical Basis of Radiation Biology. London, UK: Taylor & Francis, 1987.
218. Gollapalle E, Wang R, Adetolu R et al. Detection of oxidative clustered DNA lesions in X-irradiated mouse skin tissues and human MCF-7 breast cancer cells. Radiat Res 2007: 167: 207-216.
219. Vijayalaxmi, Reiter R J, Meltz M L, Herman T S. Melatonin: Possible mechanisms involved in its 'radioprotective' effect. Mutat Res 1998: 404: 187-189.
220. Vijayalaxmi, Reiter R J, Meltz M L. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res 1995: 346: 23-31.
221. Vijayalaxmi, Reiter R J, Herman T S, Meltz M L. Melatonin and radioprotection from genetic damage: In vivo/in vitro studies with human volunteers. Mutat Res 1996: 371: 221-228.
222. Laurent C, Voisin P, Pouget J P. DNA damage in cultured skin microvascular endothelial cells exposed to gamma rays and treated by the combination pentoxifylline and alpha-tocopherol. Int J Radiat Biol 2006: 82: 309-321.
223. Blickenstaff R T, Brandstadter S M, Reddy S, Witt R. Potential radioprotective agents. 1. Homologs of melatonin. J Pharm Sci 1994: 83: 216-218.
224. Vijayalaxmi, Meltz M L, Reiter R J, Herman T S. Melatonin and protection from genetic damage in blood and bone marrow: Whole-body irradiation studies in mice. J Pineal Res 1999: 27: 221-225.
225. Bodo E, Tobin D J, Kamenisch Y et al. Dissecting the impact of chemotherapy on the human hair follicle. Am J Pathol 2007: 171: 1153-1167.
226. Lu Z, Hasse S, Bodo E, Rose C, Funk W, Paus R. Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Exp Dermatol 2007: 16: 37-44.
227. Tunez I, del Carmen Munoz M, Feijoo M et al. Melatonin effect on renal oxidative stress under constant light exposure. Cell Biochem Funct 2003: 21: 35-40.
228. Maestroni G J. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001: 10: 467-476.
229. Liu F, Ng T B. Effect of pineal indoles on activities of the antioxidant defense enzymes superoxide dismutase, catalase, and glutathione reductase, and levels of reduced and oxidized glutathione in rat tissues. Biochem Cell Biol 2000: 78: 447-453.
230. Jou M J, Peng T I, Yu P Z et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007: 43: 389-403.
231. Albarran M T, Lopez-Burillo S, Pablos M I, Reiter R J, Agapito M T. Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light. J Pineal Res 2001: 30: 227-233.
232. Fischer T W, Burmeister G, Schmidt H W, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: Results of a pilot randomized controlled trial. Br J Dermatol 2004: 150: 341-345.
233. Fischer T W, Fischer A, Knöll B, Hipler U C, Elsner P. Melatonin in low doses enhances in vitro human hair follicle proliferation and inhibits hair growth in high doses. Arch Derm Res 2000: 292: 147.
234. Iyengar B. Melatonin and melanocyte functions. Biol Signals Recept 2000: 9: 260-266.
235. Logan A, Weatherhead B. Post-tyrosinase inhibition of melanogenesis by melatonin in hair follicles in vitro. J Invest Dermatol 1980: 74: 47-50.
236. Patel T, Ishiuji Y, Yosipovitch G. Nocturnal itch: Why do we itch at night? Acta Derm Venereol 2007: 87: 295-298.
237. Bergasa N V, Link M J, Keogh M et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001: 96: 1563-1570.
238. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995: 346: 541-544.
239. Schwarz W, Birau N, Hornstein O P et al. Alterations of melatonin secretion in atopic eczema. Acta Derm Venereol 1988: 68: 224-229.
240. Pignone A M, Rosso A D, Fiori G et al. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis. J Pineal Res 2006: 41: 95-100.
241. O'Brien I A, Lewin I G, O'Hare J P, Arendt J, Corrall R J. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf) 1986: 24: 359-364.
242. Rupprecht M, Berg P, Koch H U, Hornstein O P. Twenty-four hour melatonin concentrations in patients with active atopic eczema and after recovery. Eur J Dermatol 1995: 5: 80-83.
243. Birau N, Schloot W. Pathological nyctohemeral rhythm of melatonin secretion in psoriasis, Klinefelter's syndrome and spina bifida. RCS Med Sci 1979: 17: 400.
244. Mozzanica N, Tadini G, Radaelli A et al. Plasma melatonin levels in psoriasis. Acta Derm Venereol 1988: 68: 312-316.
245. Kimata H. Laughter elevates the levels of breast-milk melatonin. J Psychosom Res 2007: 62: 699-702.
246. Jellimann C, Mathe-Allainmat M, Andrieux J, Renard P, Delagrange P, Langlois M. Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1 H-phenalen-2-yl)amide derivatives. J Med Chem 1999: 42: 1100-1105.
247. Bedini A, Spadoni G, Gatti G et al. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. J Med Chem 2006: 49: 7393-7403.
248. Tsotinis A, Vlachou M, Papahatjis D P et al. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines. J Med Chem 2006: 49: 3509-3519.
249. Martin V, Sainz R M, Mayo J C, Antolin I, Herrera F, Rodriguez C. Daily rhythm of gene expression in rat superoxide dismutases. Endocr Res 2003: 29: 83-95.
250. Karbownik M, Lewinski A, Reiter R J. Anticarcinogenic actions of melatonin which involve antioxidative processes: Comparison with other antioxidants. Int J Biochem Cell Biol 2001: 33: 735-753.
251. Lissoni P, Malugani F, Malysheva O et al. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: Modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Neuroendocrinol Lett 2002: 23: 341-344.
252. Lissoni P, Vaghi M, Ardizzoia A et al. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo 2002: 16: 93-96.
253. Ravindra T, Lakshmi N K, Ahuja Y R. Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 2006: 60: 523-535.
254. Lissoni P, Paolorossi F, Tancini G et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br J Cancer 1996: 74: 1466-1468.
255. Gonzalez R, Sanchez A, Ferguson J A et al. Melatonin therapy of advanced human malignant melanoma. Melanoma Res 1990: 1: 237-243.
256. Revel F G, Herwig A, Garidou M L et al. The circadian clock stops ticking during deep hibernation in the European hamster. Proc Natl Acad Sci U S A 2007: 104: 13816-13820.
257. Ackermann K, Dehghani F, Bux R, Kauert G, Stehle J H. Day-night expression patterns of clock genes in the human pineal gland. J Pineal Res 2007: 43: 185-194.
258. Brown S A, Fleury-Olela F, Nagoshi E et al. The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol 2005: 3: e338.
259. Bjarnason G A, Jordan R C, Wood P A et al. Circadian expression of clock genes in human oral mucosa and skin: Association with specific cell-cycle phases. Am J Pathol 2001: 158: 1793-1801.
260. Zanello S B, Jackson D M, Holick M F. Expression of the circadian clock genes clock and period1 in human skin. J Invest Dermatol 2000: 115: 757-760.
261. Kawara S, Mydlarski R, Mamelak A J et al. Low-dose ultraviolet B rays alter the mRNA expression of the circadian clock genes in cultured human keratinocytes. J Invest Dermatol 2002: 119: 1220-1223.
262. Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 2006: 168: 748-756.
263. Foitzik K, Krause K, Nixon A J et al. Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol 2003: 162: 1611-1621.
264. Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. Exp Dermatol 2006: 15: 83-94.
265. Martinez-Campa C, Alonso-Gonzalez C, Mediavilla M D et al. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res 2006: 40: 291-296.
266. del Rio B, Garcia Pedrero J M, Martinez-Campa C, Zuazua P, Lazo P S, Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004: 279: 38294-38302.
267. Gonzalez A, Martinez-Campa C, Mediavilla M D, Alonso-Gonzalez C, Sanchez-Barcelo E J, Cos S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br J Cancer 2007: 97: 755-760.
268. Masana M I, Soares J M Jr. Dubocovich M L. 17Beta-estradiol modulates hMT1 melatonin receptor function. Neuroendocrinology 2005: 81: 87-95.
269. Ohnemus U, Unalan M, Handjiski B, Paus R. Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. J Invest Dermatol 2004: 122: 7-13.
270. Iguchi H. Age dependent changes in the serum melatonin concentrations in healthy human subjects and in patients with endocrine and hepatic disorders and renal failure. Fukuoka Igaku Zasshi 1981: 72: 423-430.
271. Waldhauser F, Weiszenbacher G, Tatzer E et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988: 66: 648-652.
272. Diaz B L, Llaneza P C. Endocrine regulation of the course of menopause by oral melatonin: First case report. Menopause 2008: 15: 388-392.